F2-Isoprostanes Are Associated With Increased Fracture Risk in Type 2 Diabetes
Authors' conclusion
Plasma F2-isoprostanes levels in individuals with diabetes are associated with increased incident clinical fracture risk independently of baseline BMD.
Study context
- Population
- Older Black and White ambulatory adults aged 70–79 years with baseline plasma F2-isoprostanes, from the Health, Aging, and Body Composition study cohort of 3075
- Participants
- 132 vs 571
- Exposure
- Per SD increase in log plasma F2-isoprostanes, T2D vs nondiabetes
- T2Dn = 132
- Nondiabetesn = 571
- Outcome
- Incident clinical fracture risk
Methodological detailsmultivariate-adjusted Cox proportional hazard model
- Multivariate-adjusted Cox proportional hazard model
Main finding
As reported in the abstract
Incident clinical fracture per SD increase in log plasma F2-isoprostanes
Hazard ratio (95% CI)P value
T2D
1.93(1.26–2.9)
P = 0.002Nondiabetes
0.98(0.81–1.18)
P = 0.79Per SD increase in log F2-isoprostanes, as printed
- Interaction between diabetes status and F2-isoprostanes
- P for interaction < 0.001
Observational data: associations, not effects.
Further findings
Correlation of log F2-isoprostanes with total hip bone mineral density (BMD) in T2D
- Baseline total hip BMD
- r = −0.25, P = .003
- 4-year decrease in total hip BMD
- r = −0.28, P = .008
Correlation with glycoxidation or bone turnover markers
- No evidence of correlation in either group
Original publication
F2-Isoprostanes Are Associated With Increased Fracture Risk in Type 2 Diabetes. J Clin Endocrinol Metab. Published 8 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →